MDXH Q4 2025: Liquid-Based Test Volume Soars 128%, Rebalancing Growth Profile

2026-02-26 | By EarningsIQ Research

MDX Health’s Q4 2025 results showcase a pivotal shift as liquid biopsy test volumes surged 128% year-over-year, signaling a successful integration of the ExoDx acquisition and a more balanced growth trajectory across product lines. The company’s disciplined operating approach yielded continued revenue expansion, even as integration costs temporarily pressured margins. With a robust 2026 guidance and a clear focus on margin improvement, MDX Health is positioning itself to capitalize on an expanded precision diagnostics menu and growing urology market demand.

Summary

• Liquid-Based Test Acceleration: Liquid biopsy volumes now drive core growth, diversifying revenue away from tissue reliance.
• Operating Leverage in Focus: Integration of ExoDx and cost discipline underpin margin improvement plans.
• 2026 Growth Confidence: Management signals high conviction in sustained double-digit growth and EBITDA margin expansion.

Performance Analysis

MDX Health delivered a 19% revenue increase in Q4 2025, with total billable test volume up 62% year-over-year. The standout driver was the liquid-based segment—comprising Select MDX, Resolve MDX, and the newly acquired ExoDx—which saw a 128% surge, while tissue-based tests (Confirm MDX and GPS) declined 5%. This marks a significant shift in the company’s growth engine, reflecting the strategic intent behind the ExoDx acquisition and the transition of select MDX customers to the new platform.

Gross margin expanded modestly to 63.2%, attributed to economies of scale, though operating loss widened to $5.3 million due to higher headcount and integration expenses. Net loss also increased, impacted by elevated financial expenses, while adjusted EBITDA remained negative, reflecting near-term acquisition absorption. Notably, the company’s OPEX as a percentage of revenue continues to decline, underlining ongoing cost discipline even as the business scales.

• Test Mix Realignment: Liquid-based tests now represent the majority of volume, reducing dependence on tissue-based diagnostics.
• Margin Resilience: Despite integration costs, gross margin improved slightly, signaling underlying operational efficiency gains.
• Cash Position: Ending cash of $29 million provides flexibility for continued integration and growth investments.

While short-term profitability was affected by acquisition-related costs, MDX Health’s performance demonstrates a resilient growth model with clear pathways to margin improvement as integration synergies materialize.

Executive Commentary

Strategic Positioning

1. Liquid Biopsy as Growth Catalyst

Liquid biopsy, a non-invasive diagnostic test using blood or urine samples, is now the primary driver of MDX Health’s volume growth. The ExoDx acquisition enabled a rapid transition of select MDX customers, accelerating the shift toward liquid-based offerings and reducing historical over-reliance on tissue-based tests.

2. Menu Expansion and Customer Base Integration

MDX Health’s expanded test menu now covers the entire prostate cancer diagnostic pathway, enhancing cross-sell opportunities and deepening customer relationships. The ongoing integration and cross-training of the combined sales force is expected to unlock further revenue synergies in 2026 and beyond.

3. Cost Discipline and Operating Leverage

Operating expense (OPEX) control remains central, with management highlighting a multi-year trend of declining OPEX as a percentage of revenue. While integration costs temporarily pressured margins, the company expects to maintain flat OPEX in 2026, leveraging scale to drive EBITDA margin improvement toward a 10% exit run-rate.

4. Clinical Evidence and Payer Strategy

Ongoing clinical collaborations, including the Oxford GPS PROTECT study, are designed to strengthen the evidence base supporting MDX Health’s tests, potentially driving broader payer coverage and inclusion in clinical guidelines—critical levers for long-term adoption and pricing power.

5. Capital Structure Optimization

The renegotiated Exact Sciences earnout, which lowered and deferred payment obligations by nearly $20 million, enhances liquidity and provides room for continued investment in growth and integration initiatives.

Key Considerations

MDX Health’s Q4 marks an inflection in both its revenue mix and operational focus, as management executes on a multi-pronged strategy to drive sustainable growth and margin expansion.

Key Considerations:

• Volume Mix Shift: Liquid-based tests now anchor growth, reducing risk from tissue-based volume fluctuations and ASP variability.
• Integration Execution: Successful ExoDx integration is critical to realizing projected cost and revenue synergies in 2026.
• Margin Expansion Pathway: OPEX discipline and economies of scale are expected to drive a 30-point EBITDA margin swing over 24-36 months.
• Clinical Validation Leverage: Results from the Oxford GPS PROTECT trial could materially enhance clinical adoption and payer acceptance.

Risks

Integration risk remains elevated, as the full absorption of ExoDx headcount and systems could prolong near-term margin pressure if not executed efficiently. Pricing and payer dynamics, particularly for tissue-based tests, continue to introduce ASP volatility. Clinical evidence development, while promising, may not immediately translate into guideline changes or reimbursement gains, potentially delaying expected growth benefits.

Forward Outlook

For Q1 2026, MDX Health guided to:

• Continued volume growth across both tissue and liquid-based tests
• Completion of sales force integration and cross-training initiatives

For full-year 2026, management maintained guidance:

• Revenue in the $137 to $140 million range, implying approximately 28% year-over-year growth
• Exit 2026 with 10% EBITDA margin

Management highlighted several factors that will drive results:

• Balanced growth across tissue and liquid test segments
• Realization of integration synergies and continued OPEX discipline

Takeaways

MDX Health’s Q4 2025 results reflect a strategic pivot toward liquid biopsy-driven growth, underpinned by disciplined execution and a broadened diagnostic menu. The company’s ability to deliver margin expansion while integrating a major acquisition will be the key determinant of near-term value creation.

• Growth Engine Realignment: Liquid-based diagnostics now drive volume, signaling a sustainable shift in the company’s revenue model.
• Margin Pathway Credibility: OPEX management and integration progress support management’s confidence in a 10% EBITDA margin exit rate for 2026.
• Watch for Clinical and Payer Milestones: Outcomes from major studies and payer decisions will be critical catalysts for future adoption and pricing power.

Conclusion

MDX Health enters 2026 with renewed momentum as liquid-based testing redefines its growth profile and integration efforts set the stage for improved profitability. Execution on integration and clinical validation will be the key watchpoints for investors as the company targets sustained double-digit growth and margin expansion.

Industry Read-Through

MDX Health’s rapid shift toward liquid biopsy volume growth highlights a broader diagnostic industry trend favoring non-invasive, scalable solutions that can be rapidly adopted by clinicians and patients. Menu expansion and payer evidence generation are increasingly critical for diagnostics companies seeking to differentiate and defend pricing. Integration risk and OPEX discipline remain central themes for peers pursuing acquisition-driven growth in precision medicine. Investors should watch for similar volume mix shifts and margin leverage signals across the diagnostics sector as the market rewards scalable, evidence-backed platforms.

MDXH Healthcare Diagnostics Liquid Biopsy Menu Expansion Acquisition Margin Expansion